ArticlePain reports2026
Longitudinal stability of data-driven fibromyalgia phenotypes across repeated clinical assessments.
Article in Pain reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Fibromyalgia is a heterogeneous chronic condition characterized by variability in pain, psychological distress, central sensitization, and functional impairment. Cross-sectional studies have identified reproducible symptom phenotypes; however, their longitudinal stability remains incompletely understood. Methods: We analyzed longitudinal data from 821 adults with fibromyalgia recruited from 2 academic medical centers. Standardized assessments included the Revised Fibromyalgia Impact Questionnaire, Beck Depression Inventory, Central Sensitization Inventory, McGill Pain Questionnaire, and selected SF-36 functional domains. Unsupervised clustering was performed at baseline to derive symptom phenotypes, which were ordered by overall severity. Using baseline-derived model parameters, phenotype membership was assigned at subsequent visits. Phenotype transitions were examined between visit 1 and visit 2 (n = 191) and across visits 1 to 3 (n = 72) using transition matrices and alluvial visualizations. Results: Two clinically interpretable fibromyalgia phenotypes were identified at baseline, representing lower-severity/preserved function and higher-severity/global impairment profiles. Across 6-month follow-up intervals, most participants remained within their baseline phenotype (61.9% from visit 1→2 and 64.8% from visit 2→3). Transitions occurred in a minority of individuals and were primarily between adjacent severity phenotypes. Among participants with 3 or more visits, phenotype membership remained stable across repeated assessments. Conclusion: Data-driven fibromyalgia phenotypes demonstrate substantial longitudinal stability, supporting their validity as enduring clinical constructs rather than transient symptom states. These findings support phenotype-based stratification for longitudinal research and precision treatment approaches in fibromyalgia. Longitudinal analysis shows that fibromyalgia symptom phenotypes are largely stable over time, with infrequent transitions occurring mainly between adjacent severity groups.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.